β-Blockers and risk of neuropsychiatric disorders: A systematic review and meta-analysis.

ABSTRACT:

Aims

This systematic review and meta-analysis aimed to evaluate the association between β-blocker use and neuropsychiatric adverse events, specifically focusing on short-term outcomes.

Methods

A comprehensive literature search identified studies reporting neuropsychiatric outcomes in patients using β-blockers, including randomized controlled trials and observational studies. Relative risks (RR) and 95% confidence intervals (CIs) were calculated for outcomes such as dizziness, insomnia, nightmares, drowsiness and delirium.

Results

Our analysis revealed that β-blocker use was significantly associated with an increased risk of dizziness (RR 1.72, 95% CI [1.39-2.14]; I² = 1%, 14 studies) compared to placebo. Lipophilic β-blockers, especially propranolol, showed

SUBMITTER: Eddin LE 

PROVIDER: S-EPMC11773113 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature